상세 보기
Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naive EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response.
- Bauml, Joshua;
- Cho, Byoung Chul;
- Park, Keunchil;
- Lee, Ki Hyeong;
- Cho, Eun Kyung;
- 외 15명
Citations
WEB OF SCIENCE
61- 제목
- Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naive EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response.
- 저자
- Bauml, Joshua; Cho, Byoung Chul; Park, Keunchil; Lee, Ki Hyeong; Cho, Eun Kyung; Kim, Dong-Wan; Kim, Sang-We; Haura, Eric B.; Sabari, Joshua K.; Sanborn, Rachel E.; Nagasaka, Misako; Ou, Sai-Hong Ignatius; Minchom, Anna Rachel; Gomez, Jorge E.; Curtin, Joshua C.; Gao, Grace; Roshak, Amy; Thayu, Meena; Knoblauch, Roland Elmar; Spira, Alexander I.
- 발행일
- 2021-05
- 유형
- Meeting Abstract
- 권
- 39
- 호
- 15
- 언어
- ENG
- 출판사
- LIPPINCOTT WILLIAMS & WILKINS
- 발행국가
- 미국
- ISSN
- E 1527-7755
P 0732-183X